of prazosin. Increased AUC & Cmax
of terazosin, glyburide, colchicine, doxorubicin, buspirone, midazolam, metoprolol, propranolol, everolimus, simvastatin, almotriptan, dabigatran & grapefruit juice. Increased AUC of carbamazepine, imipramine & sirolimus. Increased Cmax
& AUC of digoxin. May increase systemic bioavailability of other direct oral anticoagulants. Increased AUC, Css
of cyclosporine. Possible increase of tacrolimus, atorvastatin, lovastatin & ethanol (alcohol) levels. Sensitivity to lithium effects (neurotoxicity). Decreased oral clearance of quinidine. Decreased oral & systemic clearance of theophylline. Decreased total body & extrarenal clearance of digitoxin. Decreased plasma conc w/ phenytoin. Decreased AUC, Cmax
& oral bioavailability w/ rifampicin. Decreased bioavailability w/ sulfinpyrazone. Decreased AUC & Cmax
w/ St. John's wort. Possible increased levels w/ clarithromycin, erythromycin & telithromycin. Increased oral clearance w/ phenobarb & sulfinpyrazone. Increased AUC w/ cimetidine w/ corresponding decreased clearance. Increased Ctrough
w/ everolimus. Increased AUC & Cmax
w/ lovastatin. Increased plasma conc w/ HIV antiviral agents (eg, ritonavir). Increased risk of bleeding w/ acetylsalicylic acid. May potentiate activity of neuromuscular blockers (curare-like & depolarizing) & hypotensive effect of antihypertensives, diuretics & vasodilators. HMG CoA reductase inhibitors. Reduced efficacy of metformin when co-administered.